We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

By LabMedica International staff writers
Posted on 19 Jan 2015
Print article
Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians to diagnose, treat, and monitor patients with cancer, autoimmune disorders, and infectious diseases.

Immunosequencing, which uses NGS to quantitatively characterize the adaptive immune system, represents a multi-billion dollar opportunity given the role the immune system plays in nearly all areas of healthcare. Up to now, Adaptive has mostly focused on developing strategies and services for researchers, and Sequenta has focused on developing similar technology for use in monitoring of minimal residual disease (MRD) for patients with blood cancers. Adaptive and its collaborators also have released exciting research on the use of immunosequencing to measure the immune response to solid tumors and to immunotherapeutic drugs designed to enhance the response to cancer, which is the fastest growing class of new drugs for cancer patients.

“Our mission is to change the course of medicine through sequencing a patient's adaptive immune system. Over the past few months it has become increasingly clear that joining forces with Sequenta would accelerate our ability to make the promise of immunosequencing a reality for physicians and patients,” said Chad Robins, CEO of Adaptive. “By combining our resources, we can increase the number of clinical trials we are able to run to validate clinical applications of immunosequencing, and explore new and innovative research and development initiatives that neither of us would have been able to do alone.”

The companies anticipate a complementary integration of talent across senior management, R&D, bioinformatics, and sales. Sequenta founders Tom Willis and Malek Faham will join Adaptive’s senior leadership team reporting to Chad Robins, who will remain CEO of the combined company. Dr. Willis and Dr. John Stuelpnagel, Sequenta’s chairman, Illumina co-founder, and chairman of Ariosa Diagnostics, also will join Adaptive’s board of directors.

In addition to expanding the use of its research platform for academic and pharmaceutical researchers, the combined company will focus comprehensively on marketing the technology for measuring MRD in blood cancers. “We believe immunosequencing represents a more sensitive and accurate alternative to the current standard of care used to detect MRD in patients with blood cancers, including flow cytometry. Together, we can accelerate the adoption of this technology in clinical practice and in clinical trials for revolutionary new therapies that use MRD to determine patient specific care paradigms,” said Dr. Willis.

Chad Robins presented on behalf of the new combined company at the J.P. Morgan 33rd annual Healthcare Conference in San Francisco (CA USA), on January 12, 2015. He shared how this strategic integration will enable the company to expand its preeminent immunosequencing research platform and clinical diagnostic products. He also participated on a panel with other leaders from Foundation Medicine, Invitae, and Regeneron who are similarly focused on accelerating the adoption of NGS for diagnostic applications.

Adaptive Biotechnologies Corp. is a platform-based, diagnostic-driven company that utilizes NGS to profile T-cell and B-cell receptors. This advance enables the comprehensive characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and tracking of cancer patients.

Adaptive helps researchers make discoveries in oncology, autoimmune disorders, and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology, which is now available to facilitate the integration of immunosequencing into research centers.

Sequenta, Inc. was founded in 2008 and has focused on the development of clinical diagnostics using immunosequencing. Sequenta markets a laboratory developed test for use in the diagnosis and monitoring of minimal residual disease in blood cancers.

Related Links:

Adaptive Biotechnologies 
Sequenta


Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.